iShares S&P Mid-Cap 400 Growth ETFIJK

iShares S&P Mid-Cap 400 Growth ETF (IJK) is an exchange-traded fund that tracks the S&P Mid-Cap 400 Growth Index, a benchmark of 400 mid-sized US companies expected to grow faster than their peers. It is not, despite the issuer’s marketing, an AI-focused fund-though BlackRock’s product pages are sprinkled liberally with the acronym to catch curious clicks. The fund’s top holdings as of the latest disclosure include Copart (used vehicle auction logistics), Pool (swimming pool supplies), and Bio-Techne (biotech research tools), a trio that says more about mid-cap growth than any AI pitch ever could.

The issuer, iShares by BlackRock, markets itself as the world’s largest provider of ETFs and claims expert management and industry-leading research to justify its fee. But the fund’s mandate is simple: replicate the index as closely as possible, charge 0.25% per year, and keep the rest of the marketing fluff for the landing pages. The fund trades on Nasdaq under IJK, where liquidity is ample but price discovery is dominated by the underlying basket, not any thematic spark. The issuer’s UK site notes that most UK regulatory protections do not apply to the operation of iShares products and that compensation will not be available under the UK Financial Services Compensation Scheme in the event of default-an important caveat for British investors who may assume the same safeguards apply to global ETFs as to domestic funds.

SEC filings confirm IJK is a series of BlackRock Funds II, domiciled in the United States, and regulated under US law. The fund’s prospectus discloses a total expense ratio of 0.25%, which includes management fees and other operating expenses. The fund does not list a performance fee or performance-based hurdles; it’s a plain-vanilla wrapper charging a flat fee to hold a mid-cap growth index. FINRA’s Fund Analyzer shows the fund’s expense ratio at 0.25% and its 30-day SEC yield as of the last reported distribution at 0.58%, a yield that fluctuates with the index’s composition and market conditions.

For those tracking IJK, the practical reality is this: the fund’s price action is a slave to the S&P Mid-Cap 400 Growth Index, which is itself a slave to the fortunes of 400 mid-sized American companies. The issuer’s AI-themed product pages are a marketing overlay, not an investment thesis. The fund’s holdings, concentration risk, and fee structure are what truly drive outcomes, not the branding. Investors who buy the story of AI exposure will find a fund that holds Copart, Pool, and Bio-Techne-companies that automate nothing more exotic than logistics, supply chains, and lab work. The glossy pitch meets the index reality: a fee for a basket of growth stocks, full stop.

As of the latest data, IJK’s assets under management sit in the mid-billions, a figure that reflects its utility as a core mid-cap growth holding rather than any thematic edge. Liquidity on Nasdaq is robust, with average daily volume sufficient for most retail and institutional flows, but the fund’s tracking error versus the index is the real tell: it’s not designed to beat the benchmark, only to hug it as closely as fees and trading costs allow. The fund’s tracking method is full replication, meaning it holds the index constituents directly, which increases tracking error when index changes occur and the fund must rebalance. The issuer’s product page and SEC filings confirm the fund’s objective is to track the index’s price and yield, not to relative strength it.

What changed this week? Nothing structural. The index itself rebalances periodically, but the fund’s holdings and fee structure remain unchanged. The issuer’s AI ETF marketing blitz continues unabated, but IJK’s portfolio tells a different story-one of mid-cap growth, not artificial intelligence. The fund’s expense ratio and total cost remain the same, and the issuer’s UK disclaimers about regulatory protections are unchanged. The only novelty is the persistent gap between the thematic pitch and the index reality, a gap that the source requires readers to price into their decisions.